Compare Autozone Inc (AZO) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autozone Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Autozone Inc trades at $3,032 (market cap $49.50B), while Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M). The key difference: Autozone Inc is far larger — about 83.8× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Autozone Inc nearer its low. Which is the better fit depends on your goals.
| AZO | DNA | |
|---|---|---|
Market Cap | $49.50B | $590.53M |
Sector | Consumer Cyclical | Health |
52-Week High | $4.35K | $16.14 |
52-Week Low | $2.94K | $5.48 |
Enterprise Value | $61.88B | $627.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AutoZone (AZO) trades at $3,078.98, up 0.21% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company reported mixed recent earnings, beating in Q1 2026 but missing in Q3 2025, with revenue growing to $18.94B in 2025. Analyst sentiment remains strongly positive with a 72.73% buy rating and a consensus price target of $3,740, though recent news highlights stock volatility and competitive pressures.
The outlook for AZO is supported by solid fundamentals, including a 12.4% net income margin and aggressive share buybacks, but risks include slowing profit margin trends and bearish technical indicators. Upside potential exists if the company meets Q2 2026 EPS expectations of 54.51, though investors should monitor same-store sales growth and international expansion execution.
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
